Optimi Health secures a long-term ibogaine supply and begins finished drug product development for regulated psychedelic therapeutics and research

Optimi Health advances its pharmaceutical psychedelics strategy by securing access to ibogaine and moving into finished drug product development. The focus is on building a dependable supply chain for a controlled substance that has growing relevance in addiction-related and neuropsychiatric research, while positioning the company for regulated manufacturing and future commercialization. Ibogaine remains difficult to source at scale because of legal restrictions, quality-control demands, and sustainability concerns tied to traditional plant sources. A dedicated supply arrangement can support formulation work, compliance, and batch consistency, which are essential for investigational use and any eventual therapeutic pathway. Finished drug product development signals a shift beyond raw ingredient procurement toward dosage forms, manufacturing standards, and clinical readiness. That step matters because psychedelic companies increasingly need pharmaceutical-grade products, documented provenance, and scalable production systems to participate in research, partnerships, and tightly regulated treatment markets.